RecruitingNCT06932081
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i (ACHIEVE-SGLT2i) Registry
Sponsor
Leiden University Medical Center
Enrollment
400 participants
Start Date
Jan 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Congenital heart defect.
- Age ≥ 18 years.
- Initiated on treatment with an SGLT2i.
Exclusion Criteria1
- \- No consent for data collection.
Interventions
DRUGSGLT2 inhibitors
Treatment with any type and dose of sodium-glucose cotransporter 2 inhibitor.
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06932081
Related Trials
Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders
NCT074771971 location
Exercise MRI to Evaluate Cardiorespiratory Fitness in Children With Heart Disease
NCT063252801 location
Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease
NCT056472131 location
Influence of Lung Volume Optimization Maneuver in Ventilated Children on Cardiac Output and Lung Compliance in Children With Congenital Heart Disease Undergoing Surgical Repair and on Prevention of Need for ECMO or Shortening of ECMO Duration in Children With Severe Respiratory Failure
NCT071937191 location
HIIT in Youth With Congenital Heart Disease (MedBIKE)
NCT045758831 location